Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Virginia: - Kaiser Permanente-Burke Medical Center — Burke, Virginia
- University of Virginia Cancer Center — Charlottesville, Virginia
- Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
- Hematology Oncology Associates of Fredericksburg Inc — Fredericksburg, Virginia
- Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Virginia: - Augusta Health Center for Cancer and Blood Disorders — Fishersville, Virginia
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Virginia: - Inova Alexandria Hospital — Alexandria, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fair Oaks Hospital — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Inova Loudoun Hospital — Leesburg, Virginia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Virginia: - University of Virginia Cancer Center — Charlottesville, Virginia
- VCU Massey Comprehensive Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Virginia: - Research Site — Charlottesville, Virginia
- Research Site — Fairfax, Virginia
- Research Site — Midlothian, Virginia
- Research Site — Norfolk, Virginia
- Research Site — Richmond, Virginia
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in Virginia: - Virginia Oncology Associates — Chesapeake, Virginia
- Virginia Cancer Specialists — Manassas, Virginia
- Bon Secours Cancer Institute at Memorial Regional Medical Center — Mechanicsville, Virginia
- Virginia Cancer Specialists, PC — Reston, Virginia
- Virginia Oncology Associates — Virginia Beach, Virginia
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in Virginia: - Virginia Cancer Specialists, PC — Fairfax, Virginia
- Virginia Commonwealth University - Massey Cancer Center — Richmond, Virginia
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Virginia: - Bon Secours Cancer Institute at St. Francis ( Site 0048) — Midlothian, Virginia
- Virginia Oncology Associates (VOA) ( Site 8008) — Norfolk, Virginia
- Oncology and Hematology Associates of Southwest Virginia (BRCC) ( Site 8005) — Roanoke, Virginia
Phase 3 Recruiting Industry
This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participant…
Sponsor: BioNTech SE
NCT ID: NCT07173751
Sites in Virginia: - Bon Secours Cancer Institute at Memorial Regional — Mechanicsville, Virginia
- Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Bon Secours Cancer Institute at St. Mary's — Richmond, Virginia
Phase 3 Recruiting Industry
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…
Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Virginia: - Research Site — Norfolk, Virginia
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Shenandoah Oncology — Winchester, Virginia
Phase 3 Recruiting Industry
The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metasta…
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT06435429
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Oncology Associates, Sentara Health — Norfolk, Virginia
- Blue Ridge Cancer Care — Roanoke, Virginia
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in Virginia: - Bon Secours St. Francis Medical Center — Midlothian, Virginia
- Local Institution - 0301 — Roanoke, Virginia
- Shenandoah Oncology, P.C. — Winchester, Virginia
Phase 3 Recruiting Industry
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pemb…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06841354
Sites in Virginia: - Virginia Oncology Associates (VOA) ( Site 8002) — Norfolk, Virginia
Phase 3 Recruiting Industry
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …
Sponsor: Celcuity Inc
NCT ID: NCT06757634
Sites in Virginia: - Bon Secours St. Francis Medical Oncology Center — Midlothian, Virginia
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Virginia: - Ballad Health Cancer Care - Bristol — Bristol, Virginia
- University of Virginia Cancer Center — Charlottesville, Virginia
- Inova Schar Cancer Institute — Fairfax, Virginia
- Inova Fairfax Hospital — Falls Church, Virginia
- Henrico Doctor's Hospital — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Virginia: - USOR Virginia Cancer Specialists — Fairfax, Virginia
- USOR Virginia Oncology Associates — Norfolk, Virginia
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in Virginia: - Virginia Cancer Institute — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Virginia: - NEXT Virginia — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Virginia Cancer Specialists, PC — Fairfax, Virginia
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Virginia: - University of Virginia Health System — Charlottesville, Virginia
- Virginia Commonwealth University — Richmond, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible s…
Sponsor: 858 Therapeutics, Inc.
NCT ID: NCT06395519
Sites in Virginia: - Virginia Cancer Specialists — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Virginia: - NEXT Oncology — Fairfax, Virginia
Phase 1, Phase 2 Recruiting Industry
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurr…
Sponsor: AstraZeneca
NCT ID: NCT05417594
Sites in Virginia: - Research Site — Richmond, Virginia
Phase 2 Recruiting Network
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with ea…
Sponsor: Proton Collaborative Group
NCT ID: NCT01766297
Sites in Virginia: - Inova Schar Cancer Institute — Fairfax, Virginia
- Hampton University Proton Therapy Institute — Hampton, Virginia